Echo Therapeutics (OTC:ECTE) announced that its common stock, previously granted Over-the-Counter status, has graduated to the NASDAQ exchange.
The stock will continue to trade under the "ECTE" symbol.
“We welcome Echo Therapeutics, Inc. to the NASDAQ family of listed healthcare companies,” said Robert McCooey, Jr., senior VP of New Listings and Capital Markets, NASDAQ OMX. “Echo embodies the strategic vision and innovative thinking that characterizes our listed companies. We congratulate Echo on its listing on the NASDAQ Capital Market and look forward to supporting their continued success.”
The Franklin, Mass.-based maker of a wireless, non-invasive, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.
“The move to NASDAQ is a significant milestone for Echo and underscores our commitment to grow the value of our company and strengthen our shareholder base,” said Dr. Patrick Mooney, chairman & CEO of Echo Therapeutics, in a release filed with the Securities and Exchange Commission. “As we continue to build on the positive momentum generated throughout this year, we are very pleased to begin trading on NASDAQ and believe it will provide more liquidity for our current stockholders and increase visibility to the investment community.”